Abstract: The present disclosure relates to a compound of formula (I) wherein R1 represents a hydrogen atom, a —(C1-C6)alkyl group optionally substituted; R2 represents a hydrogen atom, a halogen atom, a —(C1-C6)alkyl group, a —(C3-C7)cycloalkyl group or a —(C2-C6)alkenyl group; R3 represents a hydrogen atom, a halogen atom, a —(C1-C6)alkyl group, a —(C3-C7)cycloalkyl group, or a —(C5-C10)heteroaryl group; X represents a sulfur or oxygen atom; and Ra and Rb represent a hydrogen atom or a —(C1-C6)alkyl group. The present disclosure also relates to a process for their preparation, to novel intermediate compounds, a medicament and a pharmaceutical compostions comprising the compounds of formula (I), as well as their therapeutic uses.

Abstract: The present disclosure relates to an injection device for administering of a dose of a medicament. The injection device includes a housing that configured to accommodates a cartridge filled with the medicament, a first component movable relative to the housing along the longitudinal direction between an initial position and a trigger position for dispensing of the dose of the medicament, a second component rotatable relative to the housing for at least one of setting of the dose or dispensing of the dose, a cavity provided in or formed by at least one of the first component and the second component, the cavity been sized to accommodate an electronic detector, and at least a first gasket fastened to one of the housing, the first component and the second component and configured to seal the cavity against ingress of impurities at least while the first component is in the initial position.

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

Abstract: Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.

Abstract: The present disclosure relates to a rotation sensor for an injection device, the rotation sensor comprising: a rotatable element configured for a mechanical engagement with a ratchet mechanism, the rotatable element comprising an outer rim and a hub is configured for transmission of a torque between the outer rim and the hub, at least one sensor attached to the rotatable element and configured to measure at least one of a mechanical force, a mechanical pressure or a mechanical strain at a portion of the rotatable element during a rotation of the rotatable element, a processor connected to the at least one sensor and configured to calculate an angle of rotation of the rotatable element on the basis of a sensor output of the at least one sensor.

Abstract: Provided herein are compounds and compositions thereof for activating nuclear factor erythroid 2-related factor 2 (Nrf2) for treating red blood cell diseases and inflammatory diseases.

Abstract: The invention relates to indole compounds of formula (I) to their preparation and to their therapeutic use.

Abstract: A self-IV injection device is provided. The self-IV device comprises fixing means to fix the device with respect to an arm of a user, an optical sensor, an IV needle, a drive, and a processor. The self-IV injection device is configured to detect, using the optical sensor, positions of marks placed on the arm of the user, and based on the detected positions of marks placed on the arm of the user, determine, using the processor, a suitable IV injection spot. The self-IV injection device also moves the IV needle, using the drive, to the determined suitable IV injection spot such that the IV needle penetrates a vein of the user.

Abstract: The disclosure relates to a detector arrangement for detecting a position of an object with regard to a first direction, wherein the object includes a front edge and a rear edge separated from each other in the first direction and wherein the object is movable relative to the detector arrangement in the first direction. The detector arrangement includes a first detector configured to detect electromagnetic radiation, the first detector including a first detection area sensitive to the electromagnetic radiation, wherein the detection area is confined by a first detection front edge and by a first detection rear edge, wherein the first detection front edge is separated from the first detection rear edge in the first direction. At least one of the first detection front edge and the first detection rear edge extends non-parallel to at least one of the front edge and the rear edge of the object.

Abstract: A drug delivery device, comprising housing comprising one or more bridging contacts; a movable dial located at least partially within the housing and arranged to move relative to the one or more bridging contacts, the movable dial comprising a series of conductive strips on an exterior surface of the movable dial, wherein the one or more bridging contacts selectively connect and disconnect conductive strips of the series of conductive strips as the movable dial moves to provide alternating electrical signals; at least one electronic component configured to: detect the alternating electrical signals; determine whether the alternating electrical signals are indicative of contact between conductive strips of the series of conductive strips and the one or more bridging contacts; and based on the alternating electrical signals, determine a medicament dosage programmed into the drug delivery device.

Abstract: Systems and methods for generating potential medicinal molecules using memory networks are descried. A method for generating analogs of a molecule includes: receiving one or more initial molecular structures; generating one or more of token string representations for each of the one or more initial molecular structures, each token string representation corresponding to an analog of a corresponding initial molecular structure. Generating the token string representations of analogs includes, for each further token string representation: sequentially processing a token string representation of a substructure of the corresponding initial molecular structure using a memory network; and subsequent to processing the token string representation of a substructure, sampling one or more additional tokens using the memory network. The token string representations each comprise a plurality of tokens representing predefined structures of a molecule.